Biogen CEO to step down as the drugmaker plans further Aduhelm cost cuts

[ad_1]

Biogen's Chief Executive Officer Michel Vounatsos is stepping down as it is grappling with Medicare restricting coverage for its Alzheimer's drug Aduhelm.

[ad_2]

Source link